OneChain Immunotherapeutics — Seed · €6.7M

Barcelona CAR-T cell therapy developer OneChain Immunotherapeutics, a 2020 spin-off of the Josep Carreras Leukaemia Research Institute, closed a €6.7M pre-Series A round led by Invivo Capital to advance its CARxALL clinical trial and allogeneic platform. The company separately reported €2.5M from the European Innovation Council, which is not part of this round.